Literature DB >> 2828700

Prior herpes simplex virus type 2 infection as a risk factor for HIV infection.

S D Holmberg1, J A Stewart, A R Gerber, R H Byers, F K Lee, P M O'Malley, A J Nahmias.   

Abstract

Antibodies to cytomegalovirus (CMV), Epstein-Barr virus (EBV), and herpes simplex viruses types 1 and 2 (HSV-1, HSV-2) in three sequential serum samples from 62 men who did and 61 men who did not develop human immunodeficiency virus (HIV) infection at the time of the final (third) serum specimen were studied. Antibody titers to CMV, EBV, and HSV-1 did not significantly rise in or differ between men who did or did not get HIV infection. However, we found that 32 (68%) of 47 HIV seroconverters had antibodies to HSV-2 at the time the third specimen was drawn, whereas only 26 (46%) of 57 men who remained HIV seronegative had HSV-2 antibody positivity. Seroconversion to HSV-2 between any two serum specimens was found in 11 (42%) of the 26 HIV seroconverters but in only five (14%) of 35 men who remained HIV seronegative. The association between HSV-2 seropositivity (or seroconversion) and subsequent or concurrent HIV seroconversion remained when we controlled for factors known to influence HIV infection, including age, number of sexual partners, and percentage of sexual acts involving receptive anal intercourse. These serologic studies do not support the role of CMV, EBV, or HSV-1 in HIV infection but do suggest that HSV-2 infection is a risk factor for subsequent or concurrent HIV infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828700

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  66 in total

1.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Understanding the scourge of HIV/AIDS in sub-Saharan Africa.

Authors:  Joseph Inungu; Sarah Karl
Journal:  MedGenMed       Date:  2006-11-09

3.  In Vitro and In Vivo Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection.

Authors:  James Hopkins; Tejabhiram Yadavalli; Rahul Suryawanshi; Farreh Qatanani; Ipsita Volety; Ram Koganti; Aqsa Iqbal; Deepak Shukla
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  HIV seroprevalence surveys in sexually transmitted disease clinics.

Authors:  I M Onorato; E McCray; M Pappaioanou; R Johnson; S Aral; A M Hardy; T J Dondero
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

5.  Identifying anti-HSV compounds from unrelated plants using NMR and LC-MS metabolomic analysis.

Authors:  Gerhard Prinsloo; Jacques Vervoort
Journal:  Metabolomics       Date:  2018-09-28       Impact factor: 4.290

6.  Efficiency of reconstitution of immunoglobulin g from blood specimens dried on filter paper and utility in herpes simplex virus type-specific serology screening.

Authors:  Wayne R Hogrefe; Carolyn Ernst; Xin Su
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

7.  Herpes simplex virus type 2 risks in female sex workers in the China-Vietnam border county of Hekou.

Authors:  Jun Jie Wang; Zhi Bin Zhu; Xi Yang; Jing Wu; Hai Bo Wang; Lin Feng; Guo Wei Ding; Jessie L Norris; Ning Wang
Journal:  Biomed Environ Sci       Date:  2012-12       Impact factor: 3.118

8.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

Review 9.  AIDS-related behavioral research and nursing.

Authors:  A Skinner; L Walls; L S Brown
Journal:  J Natl Med Assoc       Date:  1991-07       Impact factor: 1.798

Review 10.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.